Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

NCT01333865 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01333865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01333865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2010
Completion date
July 31, 2014
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorders